



IGF Oncology – A Dagda Certified Social Impact Company

IGF Oncology, LLC is a BioTech Solutions Company.

IGF Oncology, LLC, a Minnesota company registered in Delaware, was formed to develop its novel and proprietary family of new anti-cancer chemotherapy drugs with reduced toxicity. With help from oncology biotech investors, IGF leadership is working towards better treatments and new hope for cancer patients through innovative new drugs that reduce the strain on the body while significantly increasing the chances for positive outcomes.

IGF is developing groundbreaking cancer treatments that can help physicians seek and destroy the most dangerous and aggressive cancer cells.

Oncology biotech companies are popping up all over the world, but there are no other oncology biotech companies like IGF Oncology. Company Founder and President Dr. Hugh McTavish is both a practicing patent attorney and a Ph.D. biochemist with extensive laboratory experience. He is a cancer survivor himself, and he knows first-hand how horrible chemotherapy can be. Now, he is dedicated to finding better, more effective anti-cancer drugs.

IGF is developing new focused cancer drugs that are more targeted to tumors, with less of the drug reaching and affecting healthy cells. We have shown these drugs are more effective and have less side effects than conventional cancer chemotherapy drugs. IGF is in Phase 2 clinical trials at the Mayo Clinic now with our lead drug candidate IGF-MTX. IGF Oncology is socially impactful in bringing to market treatments for diseases (forms of cancer) that are currently incurable or have no effective treatments. IGF drugs also have less side effects and are not as unpleasant for patients than current chemotherapy cancer drugs which significantly reduces the suffering of the patient and all those who care for the patient personally or professionally.

Our mission isn't merely to become a leader among oncology biotech companies. First and foremost, we want to develop and bring to patients new targeted cancer chemotherapy drugs that have reduced side effects and improved effectiveness compared to existing chemotherapy cancer drugs. By targeting IGF-1 receptors on malignant cancer cells, IGF Oncology is developing groundbreaking cancer treatments that can help physicians seek and destroy the most dangerous and aggressive cancer cells.

Copyrighted, Confidential, & Proprietary Property of Dagda Partners, LLC. All Rights Reserved. 2018.



We are conducting a Phase 1b/2a clinical trial of our lead drug candidate IGF-methotrexate in patients suffering from a deadly blood cancer called myelodysplastic syndrome (MDS) at the Mayo Clinic.

IGF Targeted Chemotherapy Drugs

The company's first targeted chemotherapy drug is an IGF-methotrexate conjugate. This involves the standard chemotherapy drug methotrexate chemically attached to an engineered form of the hormone insulin-like growth factor (IGF). The IGF-methotrexate zeroes in on IGF receptor proteins on cancer cells to specifically deliver the drug to cancer cells. In contrast, healthy cells receive very little drug. Testing in mice shows the IGF-methotrexate conjugate is more effective than methotrexate even when used at 6-times lower dose. The drug has completed human Phase I clinical trials and is now in a Phase 1a/2b clinical trial in myelodysplastic syndrome at the Mayo Clinic.

The company's second candidate drug acts by a different proprietary mechanism. It also targets a receptor that is greatly overexpressed on cancer cells and thereby selectively kills cancer cells. We plan human clinical trials of this in ovarian cancer.

Bio-Tech Impact

There is an immediate need for bio-tech companies to regard the social environment as the key strategy issue in long range planning due to the pervasiveness of social influence. Through perceptions of need, society can influence resource allocation and exercise public control over most facets of innovation, production, distribution and marketing of drugs and in the funds available by controlling prices and profits.

IGF Impact

Impact investments can be defined as investments in companies, organizations, funds and financial instruments with the intent of generating social or environmental impact and a modest financial return. The strategy formulated by IGF Oncology is one that allows the investor to be in control of the balance between financial return and social impact giving. This is imperative as it allows a spectrum of possibilities and outcomes for investors: for example, Private Foundations can achieve social growth not only with their 5% required annual payout, but also with their 95% endowment that remains invested .

IGF has little to no environmental impact from our operations, especially relative to the profit and social benefit we can create. Our environmental impact is primarily manufacturing our

Copyrighted, Confidential, & Proprietary Property of Dagda Partners, LLC. All Rights Reserved. 2018.



product which uses very little natural resources. The main component is a protein produced by fermentation. This is a biological process that produces only natural biological wastes. The other component manufactured is a toxic drug, such as methotrexate, where the byproducts of manufacturing are mostly non-toxic and disposed of in compliance with all laws and regulations with very minimal environmental impact. The only greenhouse gas emitted from our activities is CO₂ and those emissions are minimal. Certainly the environmental impact is very small compared to the health, economic, and social benefit from our company's products.

The market size of sustainable, responsible and impact investing for 2016 in the US alone, was \$8.72 trillion, or one-fifth of all investment under professional management.


IGF Technology

IGF is very closely linked to cancer. The defining feature of a cancer cell is that the cell divides uncontrollably, and the natural biological role of the hormone IGF is to cause cells to divide. So perhaps it should not be surprising that one study found the IGF receptor is 43-times more abundant on breast cancer cells than on normal breast tissue. IGF has also been linked to most other types of cancer. The concept for the technology platform is supported by an abundance of scientific literature. The company's first candidate drug is a conjugate in which the standard cancer chemotherapy drug methotrexate is attached to an engineered form of IGF. Our testing shows the IGF-methotrexate conjugate, even at 6-fold lower concentration, is more effective than unconjugated methotrexate against a prostate cancer model in mice. That is, IGF-methotrexate is more effective than methotrexate even at 1/6 of the dose of methotrexate.

By targeting much more specifically to cancer cells, the company's drugs largely spare non-cancerous cells and have greatly reduced side effects compared to conventional chemotherapy drugs. Not only do malignant cells have more IGF-1 receptors than healthy cells, but the most dangerous and aggressive cancer cells have been found to have the most IGF-1 receptors. Thus, not only does the company's technology target cancer cells over healthy cells, but it targets the most aggressive cancer cells more than the less important cancer cells.

The company's technology targets chemotherapy much more specifically to cancer cells, and thereby spares healthy cells. This results in increased effectiveness and decreased side effects

with the drugs. The target for our drugs is a specific receptor that is 43-times more numerous on cancer cells than healthy cells (Figure 1).



IGF Oncology is at the forefront of offering a more effective, less painful solution to many cancer patients who currently have no other option than traditional chemotherapy. IGF is working with medical communities to develop and release their drugs in an effort to bring hope to cancer patients worldwide.

Board of Directors

Hugh McTavish Founder and President

Dr. Hugh McTavish, the Company's Founder and President, is a practicing patent attorney and a Ph.D. biochemist with extensive experience in the laboratory. He is also the inventor of the company's technology. Dr. McTavish is the lead author of several refereed scientific publications, and the inventor of several issued patents and pending patent applications. He received his Ph.D. in biochemistry from the University of Minnesota in 1992, and his J.D. from the University of Minnesota in 2001.



Arkadiusz Dudek

Arkadiusz Dudek, M.D., Chief Medical Officer, is Professor of Hematology/Oncology and Director of Oncology Clinical Trials at the University of Illinois Chicago.

Dr Dudek has over 18 years of cancer clinical research experience, over 18 years in the clinical management of mesothelioma, lung cancer, kidney cancer, and malignant melanoma, and over 13 years in the field of tumor angiogenesis, signal transduction, and cancer immunotherapy. His expertise is in design and execution of clinical trials for cancer therapy with a special interest in the development of novel cancer therapeutics. He has 17 years of serving in several leadership positions in clinical trial offices at the University of Minnesota and the University of Illinois. He chairs and manages a broad range of clinical trials (from phase 1 through phase 3, from cooperative group, investigator-initiated, and industry sponsored studies) that are either therapeutic or non-therapeutic studies.



Ronald Way

Ronald Way, Director, is a Director of other Pharmaceutical and Medical Device companies, and has previously worked in public relations and journalism, as a staffer in the U.S. senate

Copyrighted, Confidential, & Proprietary Property of Dagda Partners, LLC. All Rights Reserved. 2018.



IGF Oncology, a Dagda Certified Social Impact Company.

After careful consideration and documentation, Dagda Certifies that IGF Oncology is a Socially Impactful company. Based on the GIIN standards met below, outlining the impactful outcomes possible from each new drug released and the affect on the patient population and healthcare system worldwide.

Social Impact:

- Disease-specific prevention and mitigation
- Generate Funds for Charitable Giving
- Equality and empowerment
- Health improvement
- Income/productivity growth



Social Impact:

Disease-specific prevention and mitigation

IGF Oncology was formed to develop its novel and proprietary family of new anti-cancer chemotherapy drugs with reduced toxicity and reduced pain in patients. Should their treatments be approved by the FDA and other governing bodies worldwide, this would ultimately lower the aforementioned costs in both physical treatment costs and emotional distress costs in patients, while reducing mortality rates.

The Agency for Healthcare research and Quality (AHRQ) estimates that the direct medical costs (total of all health care costs) for cancer in the US in 2015 were **\$80.2 billion**.

- 52% of this cost is for hospital outpatient or doctor office visits
- 38% of this cost is for inpatient hospital stays

One of the major costs of cancer is cancer treatment. But lack of health insurance and other barriers to health care prevent many Americans from getting optimal health care.

According to the US Census Bureau, about 28 million people (9%) in the US were uninsured in 2016. The percentage of uninsured ranged from 3% in Massachusetts to 17% in Texas.

And according to *Cancer Facts & Figures 2018*, “Uninsured patients and those from many ethnic minority groups are substantially more likely to be diagnosed with cancer at a later stage, when treatment can be more extensive, costlier, and less successful.” This year, about 609,640 Americans are expected to die of cancer that’s more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. Cancer costs us billions of dollars. It also costs us the people we love. Reducing barriers to cancer care is critical in the fight to eliminate suffering and death due to cancer. Cancer treatments, such as chemotherapy, radiotherapy and hormonal treatments can have direct physical effects on the patient. Some of these can cause psychological problems or make them worse. Some patients may lose the ability to be independent. Others find that energy levels plummet and activities that were once a source of enjoyment are no longer possible. Care must be given to allow the cancer patient to experience their disease in whatever manner is best for them.

Patients frequently experience a process similar to grieving after diagnosis and during palliative or end-of-life care. There is evidence to support the existence of PTSD within both cancer survivors and cancer patients. This is a direct result of traumatic experiences associated with the disease, and because the potential for a fatal prognosis is high. Cancer treatments can also cause depression and anxiety. A side effect of chemotherapy known as chemo brain can cause fatigue, depression, mental fog, and other forms of cognitive impairment.

IGF Oncology is bringing to patients new targeted cancer chemotherapy drugs that have reduced side effects and improved effectiveness compared to existing chemotherapy cancer drugs. If approved, these new treatments will significantly reduce the suffering of cancer patients while at the same time reducing the costs.



Health Improvement

At the very heart of IGF Oncology's business model is providing more effective and less expensive treatments for cancer with a focus on reducing the mental, physical and monetary costs of chemotherapy. Health improvement describes the work to improve the health and wellbeing of individuals or communities through creating and enabling better treatments and encouraging healthy lifestyle choices as well as addressing underlying issues such as poverty, lack of educational opportunities and other such areas.

In the US 2017 total cancer treatment spending topped 125 Billion. Those numbers don't include the unreported and uncovered costs, such as nurses, acupuncture, psychotherapy, personal travel, supplements and caregivers' expenses. I spent many thousands of dollars in such costs for each of my cancers, and that's far from unusual. Of course, those numbers also don't include the personal costs borne by families and individuals, nor the follow-on effects of cancer treatment in the form of future weaknesses, illnesses, lost wages and lower productivity. Bottom line, cancer diagnosis is a costly endeavor mentally, physically and monetarily. The affects of a cancer diagnosis can be tracked through the patient's entire social family including immediate family and friends down to co-workers and acquaintances. Any improvement in the treatment process will have a positive effect on the health of all patients and all those who surround and are affected by them. IGF Oncology seeks to decrease the suffering of every chemotherapy patient by reducing harmful side effects while reducing costs and increasing the productivity of every healthcare dollar.

Income/productivity growth

When looking at what makes an economy grow in the long run, we can begin by examining how output is created. Some use a combination of labor and capital to produce their output. Labor consists of the workers and employees who produce, manage, and process production. Capital describes both the ideas needed for production and the actual tools and machines used in production. Ideas and other intellectual property are called human capital. Machinery and tools are called physical capital. IGF Oncology seeks to increase productivity by reducing costs.

In 1996 America's total medical costs hit a new record of \$3.4 trillion, according to the federal government. That's about 18 percent of the country's total GDP, meaning one out of every six dollars we spent in 2016 went to health care. The national doctor bill dwarfs anything else we spend money on, including food, clothing, housing, or even our mighty military. If that \$3.4 trillion were spread equally throughout the population, the bill would come to some \$10,350 for every man, woman and child in the country. But fortunately—for most of us, anyway—the cost of health care is not equally distributed. Rather, a small number of Americans run up most of the expense. The biggest medical costs are concentrated on a fairly small segment of the population—people with one or more chronic illnesses, plus victims of accidents or violent crime. The cost is so concentrated, in fact, that an estimated five percent of the population accounts for 50 percent of total medical costs. Including in that 5% are cancer patients. The cost to deliver high-quality cancer care is rising as a result of inflation, increasing regulatory



burden, and increasing overhead costs—not the least of which is the need for additional personnel to meet payers' administrative demands. An accumulating body of data suggests that patients are deferring treatment because of high out-of-pocket costs.

IGF aims to reduce many of the costs associated with traditional chemotherapy. A reduction in any of these costs would significantly change the landscape of medical costs worldwide, and as a result free-up capital for investments across the spectrum which ultimately increases productivity of each healthcare dollar spent, as it goes further.

Generate Funds for Charitable Giving

An important aspect of IGF Oncology's commitment to responsible corporate behavior is the exercise of social responsibility through philanthropic donations and non-commercial sponsorship. IGF Oncology's approach to philanthropic donations and non-commercial sponsorship mirrors their responsible business model and innovative culture. By selectively developing, supporting and implementing innovative solutions together with competent partners based on core knowledge and skills, measurable results and lasting improvements for sustainable impacts for society. This collaborative and value based approach demonstrates that both IGF Oncology and its partners are committed to effective outcomes. IGF Oncology's emphasis is on projects making a real difference through innovation, collaboration, quality and sustainability. When assessing projects, IGF focuses on the potential impact rather than on the cost. Considerations are on impact, not material return on investment, the measure of success or value. IGF believes that good corporate citizenship should be a matter of course and is not something to be undertaken for publicity purposes. IGF believes, through its participating partners, that their technology will become a major provider of materials and products to cancer treatment efforts globally.

Equality and empowerment:

Empowering women and achieving gender equality requires intentional actions and deliberate policies. These policies are based on concrete business practices and have inspired companies around the world to tailor existing policies and programmes – or establish needed new ones – to realize women's empowerment. IGF Oncology's management is committed to the following initiatives:

- Measure and report on women in leadership roles
- Require men and women to be on interview panels
- Roll out parental leave that gives fathers and parents of adopted children the same amount of leave as mothers (provided they are the primary caregiver)
- Roll out healthcare benefits to cover same sex partners
- Aim for minimum 40% of female vendor representation on their vendor panel